Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.

OBJECTIVE: Prostate cancer cells secrete the unique protease human glandular kallikrein 2 (hK2) that represents a target for proteolytic activation of cytotoxic prodrugs. The objective of this study was to identify hK2-selective peptide substrates that could be coupled to a cytotoxic analogue of th...

Full description

Bibliographic Details
Main Authors:	Janssen, S, Jakobsen, C, Rosen, D, Ricklis, R, Reineke, U, Christensen, S, Lilja, H, Denmeade, SR
Format:	Journal article
Language:	English
Published:	2004

Similar Items

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
by: Janssen, S, et al.
Published: (2006)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
by: Denmeade, SR, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
by: Olsson, A, et al.
Published: (2004)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
by: Becker, C, et al.
Published: (2000)

Standardization of two immunoassays for human glandular kallikrein 2.
by: Haese, A, et al.
Published: (2003)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
by: Väisänen, V, et al.
Published: (2004)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
by: Steuber, T, et al.
Published: (2005)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)

The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin.
by: Olsson, A, et al.
Published: (2004)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
by: Olsson, A, et al.
Published: (2005)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
by: Haese, A, et al.
Published: (2000)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
by: Väisänen, V, et al.
Published: (2006)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
by: Ulmert, D, et al.
Published: (2009)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

Combinatorial peptide libraries
by: 293759 Cabilly, S.
Published: (1997)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
by: Haese, A, et al.
Published: (2005)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
by: Björk, T, et al.
Published: (2001)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics
by: John T. Isaacs, et al.
Published: (2021-12-01)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
by: Vickers, A, et al.
Published: (2011)

Design of Tetra-Peptide Ligands of Antibody Fc Regions Using In Silico Combinatorial Library Screening
by: Marko Jukič, et al.
Published: (2023-08-01)

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
by: Singh, P, et al.
Published: (2009)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
by: Bruun, L, et al.
Published: (2004)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

Phage Display of Combinatorial Peptide Libraries: Application to Antiviral Research
by: Bernadette Heyd, et al.
Published: (2011-04-01)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
by: Lilja, H, et al.
Published: (2007)